Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 17:18:3825-3836.
doi: 10.2147/OPTH.S498973. eCollection 2024.

Outcomes of Ahmed Glaucoma Valve Implantation with Subsequent Trans-Scleral Diode Cyclophotocoagulation as the Main Intervention if IOP Remained Medically Uncontrolled

Affiliations

Outcomes of Ahmed Glaucoma Valve Implantation with Subsequent Trans-Scleral Diode Cyclophotocoagulation as the Main Intervention if IOP Remained Medically Uncontrolled

Sunita Radhakrishnan et al. Clin Ophthalmol. .

Abstract

Purpose: To evaluate the efficacy and safety of Ahmed glaucoma valve (AGV) implantation with subsequent trans-scleral diode cyclophotocoagulation (CPC) as the main intervention if IOP remained medically uncontrolled.

Patients and methods: Charts of 108 consecutive eyes (90 patients) that underwent AGV implantation from 2003 to 2018 at a single clinical practice were retrospectively reviewed. The procedure was considered a failure if any of the following occurred: additional incisional glaucoma surgery, IOP >21 mmHg or < 20% reduction from baseline on 2 consecutive study visits after 3 months, IOP ≤ 5 mmHg on 2 consecutive study visits after 3 months, loss of light perception, or AGV removal.

Results: The mean follow-up time was 5.4 ± 3.1 years. Diode CPC was performed in 32%. The mean IOP was 24.8 ± 8.2 mmHg before intervention, and 12.5 ± 5.6 mmHg at last follow-up (p<0.0001). The mean logMAR VA decreased by 0.24 (p=0.002). The success rate was 68%. The reasons for failure were additional incisional glaucoma surgery in 7%, AGV removal in 4%, loss of light perception in 4%, inadequate IOP reduction in 13%, and IOP ≤ 5 mm HG in 6%. The probability of survival by Kaplan Meier analysis was 88%, 76% and 69% at 1, 3, and 5 years after the procedure, respectively. Complications of AGV and CPC were comparable to those previously reported in the literature.

Conclusion: The treatment approach of AGV implantation with subsequent trans-scleral diode CPC, as needed, was successful in over 2/3rd of subjects. This study adds to the literature supporting the use of CPC when IOP is medically uncontrolled after AGV.

Keywords: cyclodestruction; laser; surgery; valved glaucoma implant.

PubMed Disclaimer

Conflict of interest statement

SR: Netra Systems Inc. (Consultant); AI: Belkin Lasers, Alcon, Ophthalmic Mutual Insurance Company (Consultant), and Eyenovia (Stock Owner). The authors report no other conflicts of interest this work.

Figures

Figure 1
Figure 1
Intraocular pressure (IOP) after Ahmed Glaucoma Valve (AGV).
Figure 2
Figure 2
Kaplan Meier Curve showing survival probability after AGV. The procedure was considered a failure if any of the following criteria were met: additional IOP lowering incisional surgery (CPC was not considered a failure), IOP >21 mmHg or less than 20% reduction below baseline on 2 consecutive study visits after 3 months, IOP ≤ 5 mmHg on 2 consecutive study visits after 3 months, loss of light perception, or AGV removal.
Figure 3
Figure 3
Kaplan Meier Curve showing survival probability after AGV. The procedure was considered a failure if any of the following criteria were met: additional IOP lowering procedure (including CPC), IOP >21 mmHg or less than 20% reduction from baseline on 2 consecutive study visits after 3 months, IOP ≤ 5 mmHg on 2 consecutive study visits after 3 months, loss of light perception, or AGV removal.

Similar articles

References

    1. Christakis PG, Zhang D, Budenz DL, et al. ABC-AVB study groups. five-year pooled data analysis of the Ahmed Baerveldt comparison study and the Ahmed versus Baerveldt study. Am J Ophthalmol. 2017;176:118–126. doi: 10.1016/j.ajo.2017.01.003 - DOI - PubMed
    1. Egbert PR, Fiadoyor S, Budenz DL, Dadzie P, Byrd S. Diode laser transscleral cyclophotocoagulation as a primary surgical treatment for primary open-angle glaucoma. Arch Ophthalmol. 2001;119:345–350. doi: 10.1001/archopht.119.3.345 - DOI - PubMed
    1. Lai JS, Tham CC, Chan JC, Lam DS. Diode laser transscleral cyclophotocoagulation as primary surgical treatment for medically uncontrolled chronic angle closure glaucoma: long-term clinical outcomes. J Glaucoma. 2005;14:114–119. doi: 10.1097/01.ijg.0000151890.41239.c5 - DOI - PubMed
    1. Feldman RM, Chuang AZ, Mansberger SL, et al.; Assists Group Outcomes of the second aqueous shunt implant versus transscleral cyclophotocoagulation treatment study: a randomized comparative trial. J Glaucoma. 2022;31(9):701–709. doi: 10.1097/IJG.0000000000002079 - DOI - PMC - PubMed
    1. Duerr ERH, Sayed MS, Moster SJ, et al. Transscleral diode laser cyclophotocoagulation: a comparison of slow coagulation and standard coagulation techniques. Ophthalmol Glaucoma. 2018;1(2):115–122. doi: 10.1016/j.ogla.2018.08.007 - DOI - PMC - PubMed

LinkOut - more resources